Recombinant Anti-DTPA x Anti-GD2 Bispecific Antibody (scIgG) (SCIGG-153)

Recombinant Anti-DTPA x Anti-GD2 Bispecific Antibody (scIgG) is designed to be expressed as two chains, each chain has the same units with their parental IgG antibodies, anti-DTPA and anti-GD2 IgGs. The two chains form heterodimer via Fc KIH technology. This BsAb can be used in pretargeting system of PET, radioimaging or radiotherapy. It can mediate targeting of radioactivity to tumor cells. It is designed for the research of Neuroblastoma; Osteosarcoma; Melanoma; Solid tumors imaging and therapy.

Datasheet INQUIRY

Specifications

Targets

DTPA & GD2

Type

Single chain IgGs

Species Reactivity

Human

Application

FuncS; Pretargeting system for radioimaging and radiotherapy

Related Disease

Neuroblastoma; Osteosarcoma; Melanoma; Solid tumors

Targets

Target 1

DTPA

Alternative Names

diethylenetriaminepentaacetic acid; DTPA; pentetic acid

Target 2

GD2

Alternative Names

Ganglioside GD2; GD2; Ganglioside; Disialoganglioside GD2

Our products and services are for research use only, and not for use in diagnostic or therapeutic procedures.

Online Inquiry

Customer Reviews and Q&As

There are currently no customer reviews or questions for Recombinant Anti-DTPA x Anti-GD2 Bispecific Antibody (scIgG) (SCIGG-153). Click the button below to contact us or submit your feedback about this product.

Recombinant Anti-DTPA x Anti-GD2 Bispecific Antibody (scIgG) (CAT#: SCIGG-153)

Specifications

Targets

Customer Reviews and Q&As